BridgeBio to Participate in March Investor Conferences

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) announced that management will participate in three March 2026 healthcare investor conferences with scheduled fireside chats in Boston and Miami.

Presentations include TD Cowen on March 2, 2026 at 3:50 pm ET, Leerink Partners on March 10, 2026 at 1:00 pm ET, and Barclays on March 11, 2026 at 12:30 pm ET. Live webcasts and 90-day replays will be available on the company website.

Key Figures

TD Cowen conference: 46th Annual TD Cowen session time: 3:50 pm EST TD Cowen date: March 2 +5 more

8 metrics

TD Cowen conference 46th Annual TD Cowen 46th Annual Healthcare Conference

TD Cowen session time 3:50 pm EST Fireside chat on Monday, March 2 at 3:50 pm EST

TD Cowen date March 2 Fireside chat on Monday, March 2 at 3:50 pm EST

Leerink session time 1:00 pm EDT Fireside chat on Tuesday, March 10 at 1:00 pm EDT

Leerink date March 10 Fireside chat on Tuesday, March 10 at 1:00 pm EDT

Barclays conference 28th Annual Barclays 28th Annual Global Healthcare Conference

Barclays date March 11 Fireside chat on Wednesday, March 11 at 12:30 pm EDT

Webcast replay window 90 days Replay of the webcasts will be available for 90 days

Market Reality Check

Price: $68.14 Vol: Trading volume 4,298,978 ...

normal vol

$68.14 Last Close

Volume Trading volume 4,298,978 vs 20-day average 3,290,154, indicating elevated activity ahead of this conference update. normal

Technical Price at $68.14 is above the $56.54 200-day MA and about 19.78% below the $84.94 52-week high.

Peers on Argus

BBIO was down 3.65% while key biotech peers showed a mixed tape: BMRN (+1.57%), ...

1 Down

BBIO was down 3.65% while key biotech peers showed a mixed tape: BMRN (+1.57%), IONS (+0.36%), SMMT (+1.66%) were up, while EXEL (‑0.91%) and ASND (‑2.39%) declined. This pattern points to stock-specific dynamics rather than a uniform sector move.

Historical Context

5 past events · Latest: Feb 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Inducement grants	Neutral	+0.8%	Equity inducement grants to 34 new employees under Nasdaq Rule 5635(c)(4).
Feb 17	Earnings scheduling	Neutral	+0.8%	Announced date and webcast details for Q4 and full-year 2025 results.
Feb 12	Phase 3 topline data	Positive	+3.7%	Positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia.
Jan 27	Inducement grants	Neutral	-0.5%	Correction and replacement of prior inducement grant disclosure for new employees.
Jan 27	Inducement grants	Neutral	-0.5%	Inducement RSU awards for 12 new employees under 2019 Inducement Equity Plan.

Pattern Detected

Recent news has mostly been routine corporate and regulatory items with modest price reactions, while the positive Phase 3 trial update on Feb 12 aligned with a stronger upside move.

Recent Company History

Over the past month, BridgeBio has reported several routine items—inducement grants on Jan 27 and Feb 17 and an earnings date announcement for Feb 24, 2026—each linked to modest price moves within ±1%. In contrast, the positive Phase 3 PROPEL 3 topline results on Feb 12 for oral infigratinib in achondroplasia coincided with a stronger 3.72% gain, highlighting clinical milestones as more impactful catalysts than corporate housekeeping updates, similar in tone to today’s conference-participation notice.

Market Pulse Summary

This announcement outlines BridgeBio’s participation in multiple March healthcare investor conferenc...

Analysis

This announcement outlines BridgeBio’s participation in multiple March healthcare investor conferences, adding visibility through fireside chats and webcasts. Historically, the stock reacted more strongly to clinical milestones, such as the positive Phase 3 data that coincided with a 3.72% move, than to routine corporate updates. Investors may watch how messaging at these events complements prior clinical results and the upcoming earnings update, with webcasts accessible for 90 days for deeper review.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences:

• TD Cowen 46^th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm EST
• Leerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDT
• Barclays 28^th Annual Global Healthcare Conference, Miami FL: Fireside Chat on Wednesday, March 11 at 12:30 pm EDT
  
  

To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

When will BridgeBio (BBIO) present at the TD Cowen conference in March 2026?

BridgeBio will present at TD Cowen on March 2, 2026 at 3:50 pm ET with a fireside chat. According to the company, a live webcast will be available and a replay will remain on the investor site for 90 days after the event.

How can investors watch BridgeBio (BBIO) fireside chats at the March 2026 conferences?

Investors can access a live webcast and later replay via the company’s investor website. According to the company, each presentation will be posted on the Events and Presentations page and replays will remain available for 90 days after each event.

What are the dates and times for BridgeBio (BBIO) presentations at March 2026 Miami conferences?

BridgeBio has two Miami fireside chats: March 10, 2026 at 1:00 pm ET and March 11, 2026 at 12:30 pm ET. According to the company, both sessions will be webcast live and posted for replay for 90 days.

Which BridgeBio (BBIO) executives will appear at the March 2026 investor conferences?

The company said members of its management team will participate in the listed fireside chats. According to the company, specific presenter names and biographies are available on the Events and Presentations page of the investor website.

How long will BridgeBio (BBIO) webcasts be available after the March 2026 conference presentations?

Recordings of the webcasts will be available for 90 days after each event. According to the company, replays are posted on the Events and Presentations page of the investor relations website for that 90-day period.